Pelthos Therapeutics PTHS ZELSUVMI Royalty Agreement — Royalty agreement, milestone
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pelthos Therapeutics in its filing.
Tagged under the XBRL concept pths:RevenueRemainingPerformanceObligationVariableConsiderationAmount.
The source filing: Pelthos Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001919246-26-000070
first commercial sale of the ZELSUVMI, a $5,000 milestone; (iv) upon the occurrence obtaining a threshold of $35,000 in aggregate net sales during four consecutive calendar quarters, a $5,000 milestone; and (vi) 30% of all non-royalty sublicense income received by the Company or its affiliates from any sublicensee. The first commercial sale milestone has been accrued within accrued expenses on the condensed consolidated balance sheets as of March 31, 2026.
Item 1. Financial Statements (unaudited)
FAQ
- What is Pelthos Therapeutics's ZELSUVMI royalty agreement — royalty agreement, milestone?
- Pelthos Therapeutics (PTHS) reported ZELSUVMI royalty agreement — royalty agreement, milestone of $5M in Q1 2026.
- How has Pelthos Therapeutics's ZELSUVMI royalty agreement — royalty agreement, milestone changed year-over-year?
- Pelthos Therapeutics's ZELSUVMI royalty agreement — royalty agreement, milestone increased by 300.0% year-over-year, from $1.25M to $5M.
- What does ZELSUVMI royalty agreement — royalty agreement, milestone mean?
- This refers to a specific financial payment triggered by the achievement of predefined clinical, regulatory, or commercial events within a licensing agreement. These payments represent contingent liabilities that impact cash flow and capital allocation strategies.
Ask your AI about Pelthos Therapeutics's zelsuvmi royalty agreement — royalty agreement, milestone.
Connect your AI assistant and compare it to peers, right in your chat.
